These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 25154392)

  • 1. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
    Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
    Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
    Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
    Willems-Jones A; Kavanagh L; Clouston D; Bolton D; ; Fox S; Thorne H
    BJU Int; 2012 Dec; 110(11 Pt C):E1181-6. PubMed ID: 23035815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.
    Lozano R; Salles DC; Sandhu S; Aragón IM; Thorne H; López-Campos F; Rubio-Briones J; Gutierrez-Pecharroman AM; Maldonado L; di Domenico T; Sanz A; Prieto JD; García I; Pacheco MI; Garcés T; Llacer C; Romero-Laorden N; Zambrana F; López-Casas PP; Lorente D; Mateo J; Pritchard CC; Antonarakis ES; Olmos D; Lotan TL; Castro E
    Eur J Cancer; 2021 Apr; 147():74-83. PubMed ID: 33626496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
    Khani F; Epstein JI
    Am J Surg Pathol; 2015 Oct; 39(10):1383-9. PubMed ID: 26076065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraductal carcinoma of the prostate.
    Robinson B; Magi-Galluzzi C; Zhou M
    Arch Pathol Lab Med; 2012 Apr; 136(4):418-25. PubMed ID: 22458904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
    Taylor RA; Fraser M; Livingstone J; Espiritu SM; Thorne H; Huang V; Lo W; Shiah YJ; Yamaguchi TN; Sliwinski A; Horsburgh S; Meng A; Heisler LE; Yu N; Yousif F; Papargiris M; Lawrence MG; Timms L; Murphy DG; Frydenberg M; Hopkins JF; Bolton D; Clouston D; McPherson JD; van der Kwast T; Boutros PC; Risbridger GP; Bristow RG
    Nat Commun; 2017 Jan; 8():13671. PubMed ID: 28067867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells.
    Porter LH; Hashimoto K; Lawrence MG; Pezaro C; Clouston D; Wang H; Papargiris M; Thorne H; Li J; ; Ryan A; Norden S; Moon D; Bolton DM; Sengupta S; Frydenberg M; Murphy DG; Risbridger GP; Taylor RA
    BJU Int; 2018 Jun; 121(6):971-978. PubMed ID: 28977728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
    Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
    Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
    Zhao J; Sun G; Zhu S; Dai J; Chen J; Zhang M; Ni Y; Zhang H; Shen P; Zhao X; Zhang B; Pan X; Nie L; Yin X; Liang J; Zhang X; Wang Z; Zhu X; Liao B; Liu Z; Armstrong CM; Gao AC; Huang H; Chen N; Zeng H
    BJU Int; 2022 Mar; 129(3):345-355. PubMed ID: 34185954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.
    Castro E; Goh C; Leongamornlert D; Saunders E; Tymrakiewicz M; Dadaev T; Govindasami K; Guy M; Ellis S; Frost D; Bancroft E; Cole T; Tischkowitz M; Kennedy MJ; Eason J; Brewer C; Evans DG; Davidson R; Eccles D; Porteous ME; Douglas F; Adlard J; Donaldson A; Antoniou AC; Kote-Jarai Z; Easton DF; Olmos D; Eeles R
    Eur Urol; 2015 Aug; 68(2):186-93. PubMed ID: 25454609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy.
    Van der Kwast T; Al Daoud N; Collette L; Sykes J; Thoms J; Milosevic M; Bristow RG; Van Tienhoven G; Warde P; Mirimanoff RO; Bolla M
    Eur J Cancer; 2012 Jun; 48(9):1318-25. PubMed ID: 22405699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
    Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
    Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
    Castro E; Goh C; Olmos D; Saunders E; Leongamornlert D; Tymrakiewicz M; Mahmud N; Dadaev T; Govindasami K; Guy M; Sawyer E; Wilkinson R; Ardern-Jones A; Ellis S; Frost D; Peock S; Evans DG; Tischkowitz M; Cole T; Davidson R; Eccles D; Brewer C; Douglas F; Porteous ME; Donaldson A; Dorkins H; Izatt L; Cook J; Hodgson S; Kennedy MJ; Side LE; Eason J; Murray A; Antoniou AC; Easton DF; Kote-Jarai Z; Eeles R
    J Clin Oncol; 2013 May; 31(14):1748-57. PubMed ID: 23569316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions.
    Miyai K; Divatia MK; Shen SS; Miles BJ; Ayala AG; Ro JY
    Int J Clin Exp Pathol; 2014; 7(5):2518-26. PubMed ID: 24966964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations.
    Khani F; Wobker SE; Hicks JL; Robinson BD; Barbieri CE; De Marzo AM; Epstein JI; Pritchard CC; Lotan TL
    J Pathol; 2019 Sep; 249(1):79-89. PubMed ID: 30993692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families.
    Thorne H; Willems AJ; Niedermayr E; Hoh IM; Li J; Clouston D; Mitchell G; Fox S; Hopper JL; ; Bolton D
    Cancer Prev Res (Phila); 2011 Jul; 4(7):1002-10. PubMed ID: 21733824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate.
    Hickman RA; Yu H; Li J; Kong M; Shah RB; Zhou M; Melamed J; Deng FM
    Am J Surg Pathol; 2017 Apr; 41(4):550-556. PubMed ID: 28009609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
    Chua MLK; Lo W; Pintilie M; Murgic J; Lalonde E; Bhandari V; Mahamud O; Gopalan A; Kweldam CF; van Leenders GJLH; Verhoef EI; Hoogland AM; Livingstone J; Berlin A; Dal Pra A; Meng A; Zhang J; Orain M; Picard V; Hovington H; Bergeron A; Lacombe L; Fradet Y; Têtu B; Reuter VE; Fleshner N; Fraser M; Boutros PC; van der Kwast TH; Bristow RG
    Eur Urol; 2017 Nov; 72(5):665-674. PubMed ID: 28511883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort.
    Trudel D; Downes MR; Sykes J; Kron KJ; Trachtenberg J; van der Kwast TH
    Eur J Cancer; 2014 Jun; 50(9):1610-6. PubMed ID: 24703897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.